Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction

Journal of Geriatric Cardiology

Volumn 11, Issue 2, 2014, Pages 100-105

  Vullaganti, Sirish ^a   Goldsmith, Jeff ^b   Teruya, Sergio ^a   Alvarez, Julissa ^a   Helmke, Stephen ^a   Maurer, Mathew S ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b Department of Medicine   (United States)

Author keywords

Anemia; Erythropoetin stimulating agents; Heart failure

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; EPOETIN ALPHA; FERROUS GLUCONATE; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

AGED; ANEMIA; ARTICLE; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EXERCISE; EXERCISE TEST; FEMALE; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; OXYGEN CONSUMPTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

EID: 84904470015     PISSN: 16715411     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1671-5411.2014.02.002     Document Type: Article

References (26)

1. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387-1393. (Pubitemid 34260433)
2. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84. (Pubitemid 43005168)
3. Holland DJ, Kumbhani DJ, Ahmed SH, et al. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction. A meta-analysis. J Am Coll Cardiol 2011; 57: 1676-1686.
4. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 2008; 300: 431-433. (Pubitemid 352040255)
5. Von Haehling S, van Veldhuisen DJ, Roughton M. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur J Heart Fail 2011; 13: 656-663.
6. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000. (Pubitemid 20034923)
7. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; 12: CD003407.
8. Cleland JG, Sullivan JT, Ball S, et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamics investigation. J Cardiovasc Pharmacol 2005; 46: 155-161. (Pubitemid 41060207)
9. Cosyns B, Velez-Roa S, Droogmans S, et al. Effects of eythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients. In J Cardiol 2010; 138: 306-307.
10. Ghali JK, Anand IS, Abraham WT, et al. Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008; 117: 526-535.
11. Palazzuoli P, Silverberg D, Iovine F, et al. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006; 152: 1096e9-1096e15.
12. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210.
13. Maurer MS, Teruya S, Chakraborty B, et al. Treating anemia in older adults with heart failure with a preserved ejection fraction (HFPEF) with epoetin alfa: single blind randomized clinical trial of safety and efficacy. Circ Heart Fail 2013; 6: 254-263.
14. Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35: 1245-1255. (Pubitemid 30206900)
15. Macdougall I. Poor response to erythropoetin: practical guidelines on investigation and management. Nephrol Dial Transplant 1995; 10: 607-614.
16. Anand I, McMurray J, Whitmore J, et al. Anemia and its relationship to clinical outcomes in heart failure. Circulation 2004; 110: 149-154. (Pubitemid 38924582)
17. Ngo K, Kotecha D, Walters JA, et al. Erythropoesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010; CD007613.
18. Kotecha D, Ngo K, Waltera JA, et al. Erythropoetin as a treatment of anemia in heart failure: Systematic review of randomized trials. Am Heart J 2011; 161: 822-831.
19. Pfeffer MA, Burdmann EA, Chen ME, et al. A trial of darbopoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
20. Daniel G, Hurley D, Whyte JL, et al. Use and cost of erythropoiesis- stimulating agents in patients with cancer. Curr Med Res Opin 2009; 25: 1775-1784.
21. Chaves PH, Semba RD, Leng SX, et al. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: the Women's Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci 2005; 60: 729-735. (Pubitemid 40881179)
22. Anker SD, Comin Colet J, Filppatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
23. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2003; 131: 5685-5805.
24. Zhu YI, Hass JD. Altered metabolic response of iron-depleted nonanemic women during a 15-km time trial. J Appl Physiol 1998; 84: 1768-1775. (Pubitemid 28225920)
25. Brownlie T, Utermohlen V, Hinton P, et al. Tissue iron deficiency without anemia impairs adaption in endurance capacity after aerobic training in previously untrained women. Am J Nutr 2004; 79: 437-443. (Pubitemid 41115588)
26. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590. (Pubitemid 28385655)